|
Title
|
|
|
|
CSF-1 and Ang-2 serum levels - prognostic and diagnostic partners in non-small cell lung cancer
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Background Lung cancer is the most incident and lethal form of cancer, with late diagnosis as a major determinant of its bad prognosis. Immunotherapies targeting immune checkpoints improve survival, but positive results encompass only 30%-40% of the patients, possibly due to alternative pathways to immunosuppression, including tumour-associated macrophages (TAM). Colony stimulating factor-1 (CSF-1) is implicated in TAM differentiation and recruitment to tumours and in tumour angiogenesis, through a special setting of Tie-2-expressing macrophages, which respond to angiopoietin-2 (Ang-2). We evaluated the role of serum levels of CSF-1 in non-small cell lung cancer (NSCLC) prognosis and whether these could serve as biomarkers for NSCLC detection, along with Ang-2. Participants and methods We prospectively studied an unselected cohort of 145 patients with NSCLC and a group of 30 control individuals. Serum levels of Ang-2 and CSF-1 were measured by ELISA prior to treatment. Results Serum levels of CSF-1 and Ang-2 are positively correlated (p<0.000001). Individuals with high serum levels of CSF-1 have a 17-fold risk for NSCLC presence and patients with combined High Ang-2/CSF-1 serum levels present a 5-fold increased risk of having NSCLC. High Ang-2/CSF-1 phenotype is also associated with worst prognosis in NSCLC. Conclusions Combined expression of CSF-1 and Ang-2 seems to contribute to worst prognosis in NSCLC and it is worthy to understand the basis of this unexplored partnership. Moreover, we think CSF-1 could be included as a biomarker in NSCLC screening protocols that can improve the positive predictive value of the current screening modalities, increase overall cost effectiveness and potentially improve lung cancer survival. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
ESMO Open / European Society for Medical Oncology.
| |
|
Publication
|
|
|
|
BMJ Publishing Group
,
2018
| |
|
ISSN
|
|
|
|
2059-7029
| |
|
DOI
|
|
|
|
10.1136/ESMOOPEN-2018-000349
| |
|
Volume/pages
|
|
|
|
3
:5
(2018)
, 6 p.
| |
|
Article Reference
|
|
|
|
UNSP e000349
| |
|
ISI
|
|
|
|
000440615600007
| |
|
Pubmed ID
|
|
|
|
30094067
| |
|
Medium
|
|
|
|
E-only publicatie
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (open access)
|
|
|
|
| |
|